[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Lymphoma and plasma cells](https://durgical.com/en/haematology/areas/lymphoid/) › Myeloma care: bones, kidneys, infections and treatment principles

# Myeloma care: bones, kidneys, infections and treatment principles

- Treatment and support

People with myeloma now live for many years. Getting there means treating the clone and, just as much, protecting the bones, [kidneys](https://durgical.com/en/anatomy/kidney/) and immune system.

Updated Nov 15, 2026

## Key points

- Treat the clone (combinations) and the damage (bone, kidney, blood, immunity) together.
- Fit patients: induction → autologous transplant → maintenance.
- Bisphosphonate or [denosumab](https://durgical.com/en/pharmacology/denosumab/); dental check first.
- [Daratumumab](https://durgical.com/en/pharmacology/daratumumab/) interferes with crossmatching: tell the blood bank.
- [Lenalidomide](https://durgical.com/en/pharmacology/lenalidomide/) / [thalidomide](https://durgical.com/en/pharmacology/thalidomide/): [thromboprophylaxis](https://durgical.com/en/haematology/preventing-clots-in-hospital-vte-risk-bleeding-risk-and-thromboprophylaxis/) and pregnancy prevention.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Common traps
- Elsewhere in DurgiPedia

- Clinical The drug classes and their typical problems

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

Myeloma treatment has two tracks run together. The first controls the plasma cell clone with combinations of drug classes: [proteasome](https://durgical.com/en/biochemistry/enzymes/proteasome/) inhibitors, immunomodulatory drugs, anti-CD38 [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) and steroids, followed in fit patients by high-dose [melphalan](https://durgical.com/en/pharmacology/melphalan/) with autologous stem cell rescue and then maintenance. The second prevents and treats the damage the clone causes: bone lesions and fractures, high calcium, kidney injury, anaemia, infections and the toxicities of treatment. Myeloma is rarely cured, but long remissions are common.

## How to think about it

Picture the clone as a factory polluting four neighbourhoods: bone (it switches on bone-eating [osteoclasts](https://durgical.com/en/physiology/bone-remodeling/)), kidney (light chains clog the tubules), blood (it crowds out red cells) and immunity (it suppresses normal antibodies). Closing the factory is the long-term fix; meanwhile each neighbourhood needs its own clean-up crew, or the patient dies of the pollution rather than the factory.

## What to know

- Typical induction is a three- or four-drug combination, for example an anti-CD38 antibody, a proteasome inhibitor, an immunomodulatory drug and [dexamethasone](https://durgical.com/en/pharmacology/dexamethasone/).
- Fit patients usually go on to high-dose melphalan with autologous stem cell transplant, then lenalidomide maintenance; others continue a non-transplant combination.
- Relapse is expected: later lines use other drug classes, BCMA-directed [CAR-T cells](https://durgical.com/en/biochemistry/topics/gene-therapy/) and bispecific antibodies.
- Bone protection: a bisphosphonate (such as [zoledronic acid](https://durgical.com/en/pharmacology/zoledronic-acid/)) or denosumab for patients on treatment, plus [radiotherapy](https://durgical.com/en/nursing/radiation-therapy-skin-care-fatigue-and-safety-with-implants-and-radioactive-sou/) or vertebral augmentation for painful or unstable lesions.
- Kidney protection: fluids, treating high calcium, stopping [NSAIDs](https://durgical.com/en/pharmacology/classes/nonsteroidal-anti-inflammatory-drugs/) and avoiding contrast where possible, and starting anti-myeloma treatment quickly to cut light-chain production.
- Infection protection: inactivated vaccines, antiviral prophylaxis against [shingles](https://durgical.com/en/microbiology/varicella-zoster-virus/) with proteasome inhibitors and anti-CD38 antibodies, and immunoglobulin replacement for recurrent infections with low antibodies.

## How it is done (and why)

- Confirm active myeloma (organ damage or a myeloma-defining marker) and assess genetic risk on the marrow.
- Deal with emergencies first: high calcium, kidney injury, cord compression, hyperviscosity and infection.
- Decide on transplant eligibility by fitness, not by age alone.
- Start induction combining drug classes, plus bone protection and infection prophylaxis.
- Fit patients: collect stem cells, give high-dose melphalan with autologous rescue, then maintenance.
- Monitor response by paraprotein, free light chains and, increasingly, MRD on the marrow.
- At relapse, switch to drug classes the clone has not yet resisted; consider CAR-T or bispecific antibodies.

## The drug classes and their typical problems

| Class | Examples | How it works | Watch for |
| --- | --- | --- | --- |
| Proteasome inhibitor | [Bortezomib](https://durgical.com/en/pharmacology/bortezomib/) | Blocks protein disposal, so plasma cells choke on their own antibody | [Peripheral neuropathy](https://durgical.com/en/conditions/peripheral-neuropathy/), shingles reactivation |
| Immunomodulatory drug | Lenalidomide, thalidomide | Changes the clone's protein degradation and boosts immune attack | Venous thrombosis, birth defects, low counts |
| Anti-CD38 antibody | Daratumumab | Marks plasma cells for immune destruction | Infusion reactions, interference with blood bank testing |
| Steroid | Dexamethasone | Kills plasma cells directly | High [glucose](https://durgical.com/en/biochemistry/molecules/glucose/), mood change, infection |
| Bone-protecting drug | Zoledronic acid, denosumab | Switch off osteoclasts | [Osteonecrosis](https://durgical.com/en/general-pathology/osteonecrosis/) of the jaw, low calcium, kidney effects (bisphosphonate) |

## Risks and precautions

- Daratumumab binds CD38 on red cells and makes every antibody screen look positive; the blood bank must be told, and the patient's red cell type is extended before the first dose.
- Immunomodulatory drugs with steroids raise the risk of venous thrombosis, so every patient receives thromboprophylaxis matched to their risk.
- A dental check before starting a bisphosphonate or denosumab, and avoiding extractions during treatment, lowers the risk of jaw osteonecrosis.
- New back pain with leg weakness or numbness, or bladder change, is cord compression until an urgent MRI shows otherwise.
- Lenalidomide and thalidomide cause birth defects, so a strict pregnancy prevention programme applies.

## Monitoring and next step

- Response: serum and urine paraprotein, serum free light chains, and MRD on the marrow when available.
- Each visit: full count, calcium, [creatinine](https://durgical.com/en/biochemistry/molecules/creatinine/) and [albumin](https://durgical.com/en/biochemistry/enzymes/albumin/); immunoglobulin levels when infections recur.
- Before daratumumab: group, antibody screen and extended red cell phenotype or genotype.
- Before bone-protecting drugs: dental review, calcium and [vitamin D](https://durgical.com/en/biochemistry/molecules/vitamin-d/), creatinine.
- Back pain with neurological signs: whole-spine MRI the same day.

## Common traps

- **Giving NSAIDs for bone pain**: they worsen kidney injury in myeloma.
- **Ignoring a 'panreactive' antibody screen after daratumumab**: the drug causes it, so warn the blood bank before treatment starts.
- **Forgetting thromboprophylaxis with lenalidomide or thalidomide**: both drugs need it.
- **Starting a bisphosphonate without a dental assessment**: it raises the risk of jaw osteonecrosis.
- **Judging transplant eligibility by age alone**: fitness, not age, decides it.

## Test yourself

Think of the answer, then tap the question to see it.

## Why does daratumumab cause problems in the blood bank?

It binds CD38 on donor and patient red cells, so the antibody screen and crossmatch react with everything and can mask a real antibody; the red cell type is extended before treatment.

## Why are NSAIDs avoided for bone pain in myeloma?

They reduce kidney blood flow in kidneys already strained by light chains, high calcium and [dehydration](https://durgical.com/en/conditions/dehydration/), and can precipitate [acute kidney injury](https://durgical.com/en/conditions/acute-kidney-injury/).

## What is checked before starting a bisphosphonate or denosumab, and why?

A dental assessment, because these drugs can cause osteonecrosis of the jaw, especially after extractions.

## A patient starts lenalidomide with dexamethasone. Which additional preventive measure is needed?

Thromboprophylaxis, because the combination raises the risk of venous thrombosis, plus a pregnancy prevention programme where relevant.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/myeloma-care-bones-kidneys-infections-and-treatment-principles/)

## Elsewhere in DurgiPedia

- [Multiple myeloma](https://durgical.com/en/general-pathology/multiple-myeloma/)
- [Plasma cell disorders: MGUS to myeloma](https://durgical.com/en/general-pathology/plasma-cell-disorders-mgus-to-myeloma/)
- [The kidney in plasma cell disorders](https://durgical.com/en/general-pathology/the-kidney-in-plasma-cell-disorders/)
- [Spine MRI: cord compression, disc and infection](https://durgical.com/en/radiology/spine-mri-cord-compression-disc-and-infection/)
- [The mouth during cancer treatment: mucositis, dry mouth and osteonecrosis](https://durgical.com/en/dentistry/the-mouth-during-cancer-treatment-mucositis-dry-mouth-and-osteonecrosis/)
- [Cancer emergencies on the ward: cord compression, SVC syndrome, high calcium and tumour lysis](https://durgical.com/en/nursing/cancer-emergencies-on-the-ward-cord-compression-svc-syndrome-high-calcium-and-tu/)
- [Haematopoietic stem cell transplant: the immunology](https://durgical.com/en/immunology/haematopoietic-stem-cell-transplant-the-immunology/)

## Connections

## Related 6

- [A paraprotein: MGUS, smouldering myeloma, myeloma or Waldenström?](https://durgical.com/en/haematology/a-paraprotein-mgus-smouldering-myeloma-myeloma-or-waldenstrom/)
- [Amyloidosis: AL, ATTR and AA](https://durgical.com/en/haematology/amyloidosis-al-attr-and-aa/)
- [Stem cell transplantation: autologous or allogeneic, and what can go wrong](https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/)
- [Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)](https://durgical.com/en/haematology/antibodies-bispecifics-and-car-t-cells-how-they-work-and-their-emergencies/)
- [Group, screen and crossmatch: who can receive what](https://durgical.com/en/haematology/group-screen-and-crossmatch-who-can-receive-what/)
- [Leukostasis and hyperviscosity: when thick blood is the emergency](https://durgical.com/en/haematology/leukostasis-and-hyperviscosity-when-thick-blood-is-the-emergency/)

## Related conditions 6

- [Multiple myeloma](https://durgical.com/en/conditions/multiple-myeloma/)
- [Hypercalcaemia of malignancy](https://durgical.com/en/conditions/hypercalcaemia-of-malignancy/)
- [Malignant spinal cord compression](https://durgical.com/en/conditions/malignant-spinal-cord-compression/)
- [Acute kidney injury](https://durgical.com/en/conditions/acute-kidney-injury/)
- [MGUS and Waldenström macroglobulinaemia](https://durgical.com/en/conditions/mgus-and-waldenstrom-macroglobulinaemia/)
- [Amyloidosis](https://durgical.com/en/conditions/amyloidosis/)

## In Pharmacology 9

- [Bortezomib](https://durgical.com/en/pharmacology/bortezomib/)
- [Lenalidomide](https://durgical.com/en/pharmacology/lenalidomide/)
- [Thalidomide](https://durgical.com/en/pharmacology/thalidomide/)
- [Daratumumab](https://durgical.com/en/pharmacology/daratumumab/)
- [Dexamethasone](https://durgical.com/en/pharmacology/dexamethasone/)
- [Melphalan](https://durgical.com/en/pharmacology/melphalan/)
- [Zoledronic acid](https://durgical.com/en/pharmacology/zoledronic-acid/)
- [Pamidronic acid](https://durgical.com/en/pharmacology/pamidronic-acid/)
- [Denosumab](https://durgical.com/en/pharmacology/denosumab/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Multiple Myeloma](https://www.ncbi.nlm.nih.gov/books/NBK534764/) (StatPearls (NCBI Bookshelf), 2023); [Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version](https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq) (National Cancer Institute, 2025); [Multiple myeloma: MedlinePlus Medical Encyclopedia](https://medlineplus.gov/ency/article/000583.htm) (MedlinePlus, US National Library of Medicine, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/myeloma-care-bones-kidneys-infections-and-treatment-principles/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/myeloma-care-bones-kidneys-infections-and-treatment-principles/
